Neurava Expands Board with Key Appointments for Growth

Neurava Strengthens Leadership with New Board Members

Neurava, a pioneering medical device company focused on epilepsy care and management, recently made significant strides by welcoming two seasoned professionals to its Board of Directors. These strategic appointments are expected to provide unmatched expertise that will propel Neurava’s mission forward. The company has appointed Daniel (Dan) Moore, a veteran with extensive experience in medical devices, alongside John (Jed) Kay, an Operating Partner from Elevate Ventures.

Daniel Moore: A Leader in Medical Devices

With over 35 years dedicated to the medical device industry, Dan Moore brings an amazing wealth of knowledge, particularly in the field of epilepsy treatment. His previous role as CEO of Cyberonics showcased his capacity for leading substantial growth, where he raised company revenues significantly and advanced neuromodulation devices aimed specifically at epilepsy care. Furthermore, after the merger of Cyberonics with Sorin, he took on the role of Chairman at LivaNova, continuing to expand the company’s portfolio in epilepsy neuromodulation devices.

Jed Kay: Expertise in Market Access

Alongside Dan, Jed Kay is set to lend his considerable expertise in investment and commercialization. His experience at Elevate Ventures sees him engage with numerous healthcare startups, tackling intricate reimbursement and sales strategies. His profound comprehension of market access will be crucial as Neurava attempts to solidify its market position and drive growth.

Shared Excitement for Future Development

“The addition of Dan and Jed to our Board is truly exciting,” shared Jay Shah, Co-Founder and CEO of Neurava. “Their extensive backgrounds, particularly in the epilepsy and neuromodulation sectors, paired with Jed's knowledge of commercialization, will be significant assets as we advance our goals. Their strategic insights will be invaluable as we strive to deliver innovative and life-changing solutions for our patients.”

A Focus on Patient-Centered Care

Vivek Ganesh, Co-Founder and CTO of Neurava, echoed Jay’s enthusiasm. “Welcoming Dan and Jed marks an important advancement in our efforts to transform epilepsy care. Their combined expertise will enable Neurava to concentrate on data-driven, patient-centered strategies while furthering our wearable technologies that enhance the quality of life for those living with epilepsy.”

Commitment to Innovation in Epilepsy Care

Mona Chadha, a member of Neurava's Board and representative of Life Science Angels, articulated her excitement about the new Board members, stating, “Their extensive experience within medical devices and healthcare commercialization will provide Neurava with a competitive edge as we continue to innovate and make a significant impact in the epilepsy space.”

Jed Kay stated, “I am eager to join forces with the incredible team at Neurava. The potential of its wearable technology to address existing gaps for patients facing uncontrolled seizures is profound. Collaborating closely will enhance the connectivity between patients, their caregivers, and healthcare providers, ultimately delivering peace of mind.”

Looking Ahead to Transformative Opportunities

Expressing his enthusiasm, Dan Moore remarked, “Joining Neurava at such a pivotal time is truly thrilling. The opportunity to better the lives of those battling epilepsy is immense, and I look forward to working collaboratively with the team to drive innovations that will genuinely make a difference.”

About Neurava

Neurava is an innovative MedTech startup dedicated to developing state-of-the-art wearable technology designed to detect, alert, and provide insights into seizures, cardiorespiratory dysfunctions, and risks associated with SUDEP. With a strong patient-centric approach, the firm’s unique monitoring platform aims to significantly enhance the lives of millions affected by epilepsy around the globe.

Frequently Asked Questions

What is Neurava's main focus?

Neurava aims to transform epilepsy care through innovative wearable technology.

Who are the new members of Neurava's Board of Directors?

The new board members are Daniel Moore and Jed Kay, both with extensive experience in medical devices and healthcare commercialization.

What experience does Daniel Moore bring to Neurava?

Daniel Moore has over 35 years in the medical device industry, having previously served as CEO of Cyberonics and Chairman of LivaNova.

How will Jed Kay contribute to Neurava?

Jed Kay will leverage his expertise in market access and commercialization to drive Neurava's growth strategy.

What technologies is Neurava developing?

Neurava is developing wearable devices that monitor seizures and other related health functions, aiming to improve patient care.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.